Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00456040|
Recruitment Status : Completed
First Posted : April 4, 2007
Last Update Posted : April 4, 2007
|Condition or disease|
Systemic amyloidosis is a progressive disease leading to organ failure and death. Treatment has improved survival with stem-cell transplantation. Unfortunately, patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation.
The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased.
Previous trials have raised the possibility that survival may be increased in patients with amyloidosis, if chemotherapy and stem-cell transplantation is performed after a heart transplant.
We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant.
|Study Type :||Observational|
|Estimated Enrollment :||25 participants|
|Observational Model:||Defined Population|
|Observational Model:||Natural History|
|Official Title:||Characteristics of Patients With Systemic Amyloidosis and Severe Heart Failure Being Evaluated for a Sequential Cardiac and Autologous Stem Cell Transplantation|
|Study Start Date :||March 2007|
|Estimated Study Completion Date :||March 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00456040
|Principal Investigator:||Marc J Semigran, MD||Massachusetts General Hospital|